InVivoMAb anti-mouse CD28

Win SJ, Kühl AA, Sparwasser T, et al. In vivo activation of Treg cells with a CD28 superagonist prevents and ameliorates chronic destructive arthritis in mice. Eur J Immunol. 2016,46(5):1193-202. doi: 10.1002/eji.201546104

Schmidt T, Willenborg S, Hünig T, et al. Induction of T regulatory cells by the superagonistic anti-CD28 antibody D665 leads to decreased pathogenic IgG autoantibodies against desmoglein 3 in a HLA-transgenic mouse model of pemphigus vulgaris. Exp Dermatol. 2016,25(4):293-8. doi: 10.1111/exd.12919

Schuhmann MK, Kraft P, Stoll G, et al. CD28 superagonist-mediated boost of regulatory T cells increases thrombo-inflammation and ischemic neurodegeneration during the acute phase of experimental stroke. J Cereb Blood Flow Metab. 2015,35(1):6-10. doi: 10.1038/jcbfm.2014.175

Dennehy KM, Elias F, Zeder-Lutz G, et al. Cutting edge: monovalency of CD28 maintains the antigen dependence of T cell costimulatory responses. J Immunol. 2006,176(10):5725-9.